Quarterly report pursuant to Section 13 or 15(d)

Shareholders Equity (Sharebased Compensation and Share Repurchase Program)

v3.24.2.u1
Shareholders Equity (Sharebased Compensation and Share Repurchase Program)
9 Months Ended
Jun. 30, 2024
Shareholders Equity (Sharebased Compensation and Share Repurchase Program)  
Shareholders' Equity (Share-based Compensation and Share Repurchase Program)

10. Shareholders’ Equity (Share-based Compensation and Share Repurchase Program)

 

Amended and Restated 2013 Incentive Stock Plan, as amended

 

As of June 30, 2024, there were vested and unvested shares of restricted stock and stock options outstanding under the Company’s Amended and Restated 2013 Incentive Stock Plan, as amended (“Incentive Stock Plan”). The Incentive Stock Plan, as amended, provides for total shares available for restricted stock and stock options of 15,000 (7,500 restricted stock shares and 7,500 stock option shares). The Incentive Stock Plan authorizes the Compensation Committee of the Board of Directors to grant non-statutory stock options to employees. Vesting periods are established by the Compensation Committee at the time of grant.

 

As of June 30, 2024, there were 8,199 shares available to be granted under the Plan (4,052 shares available for restricted stock grants and 4,147 shares available for non-qualified stock option grants).

 

Restricted Stock

 

The Company has an annual incentive compensation program (“AICP”) for its executives which is administered under the Company’s Incentive Stock Plan. The AICP includes a long-term incentive (“LTI”) compensation program in the form of restricted stock awards comprised of two components: one that vests based on future service only, and a second that vests based on future service and performance. Initial awards under both service-only and service plus performance-based components of the AICP LTI plan are determined based on financial performance measures for the immediately preceding fiscal year.

 

The Company granted 195 shares of restricted stock under the AICP during the nine months ended June 30, 2024. Of the 195 shares granted, 164 were granted based on actual fiscal 2023 results and will cliff vest on December 1, 2026, based on future service only. Of the remaining 31 shares granted which vest based on future service and performance, 5 were granted based on fiscal 2023 results and will cliff vest on December 1, 2026, the third anniversary from their date of grant. The remaining 26 future service and performance-based shares granted were based on fiscal 2022 results and will cliff vest on December 1, 2025, the second anniversary from their date of grant. The 31 service plus performance-based restricted shares are subject to adjustment over their corresponding fiscal 2024 reporting period based on probability of achieving the fiscal 2024 financial targets set by the Company’s Board of Directors. The shares currently reported have been adjusted based on the probable outcome as compared to these financial targets. The final number of fiscal 2023 and 2022 service plus performance-based restricted shares granted will be determined once the actual financial performance of the Company is determined for fiscal 2024.

 

Share-based compensation expense attributable to restricted stock was $78 and $119 for the three-month periods and $230 and $294 for the nine-month periods ended June 30, 2024 and 2023, respectively. As of June 30, 2024, there was approximately $366 of unrecognized compensation expense related to restricted stock outstanding and the weighted average remaining vesting period for those grants was 1.06 years.

 

 

 

Number of Shares

 

 

Weighted Average Fair Value ($)

 

Non-vested restricted stock outstanding as of September 30, 2023

 

 

1,384

 

 

 

0.62

 

Granted

 

 

195

 

 

 

0.54

 

Vested

 

 

-

 

 

 

-

 

Non-vested restricted stock outstanding as of December 31, 2023

 

 

1,579

 

 

 

0.61

 

Granted

 

 

-

 

 

 

-

 

Vested

 

 

-

 

 

 

-

 

Non-vested restricted stock outstanding as of March 31, 2024

 

 

1,579

 

 

 

0.61

 

Granted

 

 

-

 

 

 

-

 

Vested

 

 

-

 

 

 

-

 

Non-vested restricted stock outstanding as of June 30, 2024

 

 

1,579

 

 

 

0.61

 

Warrants

 

The Company had 77 warrants outstanding as of June 30, 2024 and September 30, 2023 with a weighted average exercise price per share of $2 and a weighted average remaining contractual life of 0.75 and 1.50, respectively. No warrants were granted or expired during the nine months ended June 30, 2024.

 

Stock Options

 

All stock options outstanding as of June 30, 2024 and September 30, 2023 were non-qualified stock options, had exercise prices equal to the market price on the date of grant, and had expiration dates ten years from the date of grant.

 

The Company did not grant stock options during the nine months ended June 30, 2024. The Company’s stock options previously granted generally vest on annual schedules during periods ranging from two to four years, although some options are fully vested upon grant. Share-based compensation expense attributable to stock options is recognized over their estimated remaining lives and was $71 and $57 for the three-month periods and $229 and $382 for the nine-month periods ended June 30, 2024 and 2023, respectively. As of June 30, 2024, there was approximately $643 of unrecognized compensation expense related to unvested stock options outstanding, and the weighted average remaining vesting period for those options was 2.81 years.

 

A summary of stock option activity is as follows:

 

 

Number of Shares

 

 

Weighted Average Exercise Price per share ($)

 

 

Weighted Average Fair Value per share ($)

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Total Intrinsic Value of Options ($)

 

Options outstanding as of September 30, 2023

 

 

3,933

 

 

 

1.18

 

 

 

0.96

 

 

 

7.96

 

 

 

27

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited

 

 

(328 )

 

 

1.21

 

 

 

1.10

 

 

 

-

 

 

 

-

 

Options outstanding as of December 31, 2023

 

 

3,605

 

 

 

1.18

 

 

 

0.95

 

 

 

7.75

 

 

 

-

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited

 

 

(117 )

 

 

1.34

 

 

 

1.23

 

 

 

-

 

 

 

-

 

Options outstanding as of March 31, 2024

 

 

3,488

 

 

 

1.17

 

 

 

0.94

 

 

 

7.52

 

 

 

-

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited

 

 

(136 )

 

 

1.27

 

 

 

1.02

 

 

 

-

 

 

 

-

 

Options outstanding as of June 30, 2024

 

 

3,352

 

 

 

1.17

 

 

 

0.93

 

 

 

7.33

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable as of September 30, 2023

 

 

2,190

 

 

 

1.64

 

 

 

1.31

 

 

 

6.80

 

 

 

23

 

Exercisable as of June 30, 2024

 

 

2,184

 

 

 

1.47

 

 

 

1.16

 

 

 

6.53

 

 

 

-

 

 

Share Repurchase Program

 

On April 27, 2023, the Company’s Board of Directors approved a share repurchase program authorizing the Company to purchase up to an aggregate of $20 million of the Company’s currently outstanding shares of common stock. The share repurchase program continued through December 31, 2023. The repurchase program did not obligate the Company to repurchase any number of shares of common stock. The share repurchase program was conducted in accordance with Rules 10b-5 and 10b-18 of the Securities Exchange Act of 1934, as amended. Subject to applicable rules and regulations, shares of common stock were purchased from time to time in the open market transactions and in amounts the Company deemed appropriate, based on factors such as market conditions, legal requirements, and other business considerations.

 

The Company repurchased 2,717 shares of its common stock under program during the nine-month period ended June 30, 2024 at a net cost of $1,575. Upon conclusion of the share repurchase program, as of December 31, 2023, the Company repurchased 6,128 shares in aggregate (accounting for approximately 5.4% of our issued and outstanding common shares immediately prior to the program).